Photo from wikipedia
TP53‐altered myelodysplastic syndrome with excess blasts and TP53‐altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would… Click to show full abstract
TP53‐altered myelodysplastic syndrome with excess blasts and TP53‐altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
Keywords:
tp53 altered;
altered acute;
excess blasts;
acute myeloid;
syndrome excess;
myelodysplastic syndrome
Journal Title: Cancer
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!